Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average) (2013 - 2026)

Ocular Therapeutix's Shares Outstanding (Weighted Average) history runs 14 years deep, the most recent figure standing at $224.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 32.29% year-over-year to $224.1 million; the TTM figure through Mar 2026 stood at $224.1 million (up 32.29% YoY), while the FY2025 annual figure was $187.2 million, up 18.31% from the prior year.
• Shares Outstanding (Weighted Average) was $224.1 million for Q1 2026 at Ocular Therapeutix, up from $187.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $224.1 million in Q1 2026 to a low of $76.7 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $127.6 million across 5 years, with a median of $132.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) grew 0.36% in 2022, then jumped 112.47% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $76.9 million in 2022, then rose by 3.84% to $79.8 million in 2023, then soared by 98.26% to $158.3 million in 2024, then gained by 18.31% to $187.2 million in 2025, then rose by 19.68% to $224.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $224.1 million (Q1 2026), $187.2 million (Q4 2025), and $183.9 million (Q3 2025), per Business Quant data.